Deal Library / Pharma BD Deal Intelligence

Regeneron Pharmaceuticals, Inc. — Pharma Deals

The Pharma Closeout tracks 8 deals, $13.1B in disclosed deal value, 2 with a post-close Outcome Score for Regeneron Pharmaceuticals, Inc..

Median Critic Score: 78  ·  Median Outcome Score: 70

Best outcome: Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. (77)  ·  Weakest outcome: Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. (62)

All 8 deals

• Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. — 2019 · $1.0B · Worked — the deal delivered on its rationale.
• Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. — 2026 · $4.0B · Largely worked — most objectives met.
• Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. — 2026 · $2.3B
• Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited — 2026 · $2.1B
• Regeneron Pharmaceuticals, Inc. / 23andMe, Inc. — 2025 · $256M
• Regeneron Pharmaceuticals, Inc. / Tessera Therapeutics, Inc. — 2025 · $275M
• Regeneron Pharmaceuticals, Inc. / Hansoh Pharmaceutical Group Co. Ltd. — 2025 · $2.0B
• Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) — 2022 · $1.1B

← Deal Library  ·  Interactive search  ·  How we score deals